לורי שטרן: תנו לי לשחק שמנה נחשקת ומוצלחת, כמו שאני במציאות ynet.co.il - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ynet.co.il Daily Mail and Mail on Sunday newspapers.
Neuraxpharm selected for prestigious pilot program to supply medical cannabis in France
Neuraxpharm strengthens its position as a European leader in medical cannabis with the pilot program issued by The National Agency for the Safety of Medicines and Health Products
DÜSSELDORF, Germany and BARCELONA, Spain, Jan. 28, 2021 /PRNewswire/ Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the central nervous system (CNS), today announces that its affiliate Neuraxpharm France has been selected as one of winners for the participation in a pilot program for the medical use of cannabis issued by The French National Agency for the Safety of Medicines and Health Products (ANSM), together with Panaxia Labs, Israel s largest medical cannabis manufacturer.
Share this article
TEL AVIV, Israel, Jan. 26, 2021 /PRNewswire/
Dr. Dadi Segal, CEO of Panaxia Global, said, Our success in this prestigious French government tender along with our partner, Neuraxpharm, is a huge achievement for Panaxia, and we are proud to be part of the elite group of global medical cannabis leaders selected for the program. The fact that four Panaxia products met the French regulatory requirements, including sublingual tablets for the first time, serves as powerful confirmation of the uncompromising quality of the company s products. We believe the French market will become one of the world s most advanced medical cannabis markets as well as a significant growth driver for Panaxia. We are excited to take our first steps there and provide the patients in the program with innovative and quality cannabis products.
נועם בוהדנה מדגמנת: שם המשפחה המפורסם לפעמים עוזר ולפעמים מקשה ynet.co.il - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ynet.co.il Daily Mail and Mail on Sunday newspapers.